RNA P&L Curve
Atrium Therapeutics, Inc. (RNA) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $128.5M, listed on NASDAQ, employing roughly 511 people, carrying a beta of 0.37 to the broader market. Atrium Therapeutics, Inc. Led by Kathleen Gallagher, public since 2026-02-27.
A profit/loss curve charts the theoretical gain or loss of an options position across a range of underlying prices. It helps traders visualize risk, identify breakeven points, and compare strategies before committing capital.
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $128.5M
- Employees
- 511
- IPO Date
- 2026-02-27
- CEO
- Kathleen Gallagher
- Beta
- 0.37
As of Nov 13, 2026, the Atrium Therapeutics, Inc. spot price is $7.66; P&L scenarios can be constructed from the options chain. Payoff diagrams should be rebuilt from the live options chain; the preceding values are illustrative and assume a single at-the-money straddle for reference.